Department of Health and Human Services - www.hhs.gov
Department of Health and Human Services - www.hhs.gov
healthfinder.gov - A Service of the National Health Information Center, U.S. Department of Health and Human Services

 

healthfinder.gov Home   |   About Us   |   News   |   Health Library   |   Consumer Guides   |   Organizations   |   En Español   |   Kids   |   Contact Us

Home > News

Molecule Disrupts DNA Sequence in Ewing's Sarcoma

Finding could yield first targeted therapy for the rare disease, researchers say.

  • E-mail this article
  • Subscribe to news
  • Printer friendly version
  • (SOURCE: Georgetown University Medical Center, news release, April 13, 2008)

    MONDAY, April 14 (HealthDay News) -- A molecule that disrupts the oncogene that causes Ewing's sarcoma has been identified by Georgetown University Medical Center researchers.

    Ewing's sarcoma is a rare cancer that strikes children and young adults and can cause tumors to grow anywhere in the body. About 500 cases are diagnosed each year in the United States. Treatment involves a combination of five different chemotherapy drugs. An estimated 60 percent to 70 percent of patients survive over time, but many experience lingering effects from the chemotherapy.

    Ewing's sarcoma occurs when there's an exchange of DNA between two chromosomes, a process called translocation. The EWS gene on chromosome 22 fuses to the FLI1 gene on chromosome 11, creating a new gene called EWS-FLI1, which produces the fusion protein that's causes cancer.

    If further research shows that this newly identified molecule is effective, it could offer the first targeted therapy to treat Ewing's sarcoma, the researchers said. The molecule works through a so-called protein-protein interaction and could provide a model upon which to design other therapies.

    "I think this holds really wonderful promise as a unique way of targeting fusion proteins," lead investigator Dr. Jeffrey Toretsky, a pediatric oncology physician and researcher at Georgetown University's Lombardi Comprehensive Cancer Center, said in a prepared statement.

    "People thought it wasn't possible to have a small molecule that can bind between flexible proteins, but we have shown that it can be done," Toretsky said.

    He noted that the study was conducted in laboratory cells, so further research is needed before the molecule can be tested in humans.

    The study was to be presented Sunday at the annual meeting of the American Association for Cancer Research, in San Diego.

    More information

    The U.S. National Library of Medicine has more about Ewing's sarcoma.

    Copyright © 2008 ScoutNews, LLC. All rights reserved.  External Links Disclaimer Logo

    HealthDayNews articles are derived from various sources and do not reflect federal policy. healthfinder.gov does not endorse opinions, products, or services that may appear in news stories. For more information on health topics in the news, visit the healthfinder.gov health library.

    healthfinder.gov logo USA dot Gov: The U.S. Government’s Official Web Portal
    footer shadow